IDH1 and neoplasm: As a proof of the principal approach, we attempted monitoring of the pan-mutant IDH1 inhibitor BAY1436032 using 1H-MRS to measure tumor 2-HG/tCr ratios in the LNT-229 IDH1-R132H model.